<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9604391</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21634</journal-id>
<journal-id journal-id-type="nlm-ta">Drug Discov Today</journal-id>
<journal-id journal-id-type="iso-abbrev">Drug Discov. Today</journal-id>
<journal-title-group>
<journal-title>Drug discovery today</journal-title>
</journal-title-group>
<issn pub-type="ppub">1359-6446</issn>
<issn pub-type="epub">1878-5832</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30664937</article-id>
<article-id pub-id-type="pmc">6476685</article-id>
<article-id pub-id-type="doi">10.1016/j.drudis.2019.01.007</article-id>
<article-id pub-id-type="manuscript">NIHMS1520467</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Induced pluripotent stem cells for neural drug discovery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Farkhondeh</surname>
<given-names>Atena</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Rong</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gorshkov</surname>
<given-names>Kirill</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Kevin G.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Might</surname>
<given-names>Matthew</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodems</surname>
<given-names>Steven</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lo</surname>
<given-names>Donald C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA</aff>
<aff id="A2"><label>2</label>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA</aff>
<aff id="A3"><label>3</label>University of Alabama at Birmingham, Birmingham, AL, USA</aff>
<aff id="A4"><label>4</label>Retrophin, Inc., San Diego, CA, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label><italic>Corresponding author</italic>: Zheng, W. (<email>wzheng@mail.nih.gov</email>).</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>1</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2020</year>
</pub-date>
<volume>24</volume>
<issue>4</issue>
<fpage>992</fpage>
<lpage>999</lpage>
<!--elocation-id from pubmed: 10.1016/j.drudis.2019.01.007-->
<abstract id="ABS1">
<p id="P2">Neurological diseases such as Alzheimer’s disease and Parkinson’s disease are growing problems, as average life expectancy is increasing globally. Drug discovery for neurological disease remains a major challenge. Poor understanding of disease pathophysiology and incomplete representation of human disease in animal models hinder therapeutic drug development. Recent advances with induced pluripotent stem cells (iPSCs) have enabled modeling of human diseases with patient-derived neural cells. Utilizing iPSC-derived neurons advances compound screening and evaluation of drug efficacy. These cells have the genetic backgrounds of patients that more precisely model disease-specific pathophysiology and phenotypes. Neural cells derived from iPSCs can be produced in a large quantity. Therefore, application of iPSC-derived human neurons is a new direction for neuronal drug discovery.</p>
</abstract>
<abstract abstract-type="summary" id="ABS2">
<title>Teaser:</title>
<p id="P24">Patient-derived induced pluripotent stem cells are a useful model system for neural drug discovery.</p>
</abstract>
<kwd-group>
<kwd>Induced pluripotent stem cells</kwd>
<kwd>iPSC models</kwd>
<kwd>neuronal diseases</kwd>
<kwd>cell-based disease models</kwd>
<kwd>drug discovery and development</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>